Oatly Group Valuation
Is OTLY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OTLY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OTLY ($0.61) is trading below our estimate of fair value ($3.39)
Significantly Below Fair Value: OTLY is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OTLY?
Key metric: As OTLY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is OTLY's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | US$813.47m |
| Market Cap | US$383.37m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | -6.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OTLY's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.8x | ||
SENE.A Seneca Foods | 0.3x | n/a | US$452.8m |
LWAY Lifeway Foods | 1.9x | 14.4% | US$331.2m |
BGS B&G Foods | 0.3x | -0.05% | US$497.9m |
WEST Westrock Coffee | 0.7x | 15.8% | US$639.5m |
OTLY Oatly Group | 0.4x | 6.3% | US$383.4m |
Price-To-Sales vs Peers: OTLY is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.8x).
Price to Sales Ratio vs Industry
How does OTLY's PS Ratio compare vs other companies in the US Food Industry?
Price-To-Sales vs Industry: OTLY is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Food industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is OTLY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | 0.6x |
Price-To-Sales vs Fair Ratio: OTLY is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$0.61 | US$1.89 +211.5% | 52.1% | US$4.00 | US$0.85 | n/a | 8 |
| Nov ’25 | US$0.80 | US$1.97 +145.8% | 47.0% | US$4.00 | US$1.05 | n/a | 8 |
| Oct ’25 | US$0.83 | US$1.97 +136.9% | 47.0% | US$4.00 | US$1.05 | n/a | 8 |
| Sep ’25 | US$0.87 | US$1.97 +125.4% | 47.0% | US$4.00 | US$1.05 | n/a | 8 |
| Aug ’25 | US$0.94 | US$1.97 +108.1% | 47.0% | US$4.00 | US$1.05 | n/a | 8 |
| Jul ’25 | US$0.92 | US$1.98 +114.7% | 47.4% | US$4.00 | US$1.05 | n/a | 8 |
| Jun ’25 | US$1.09 | US$1.98 +81.5% | 47.4% | US$4.00 | US$1.05 | n/a | 8 |
| May ’25 | US$1.17 | US$1.98 +69.1% | 47.4% | US$4.00 | US$1.05 | n/a | 8 |
| Apr ’25 | US$1.12 | US$1.97 +75.8% | 48.3% | US$4.00 | US$1.05 | n/a | 8 |
| Mar ’25 | US$1.08 | US$1.97 +82.3% | 48.3% | US$4.00 | US$1.05 | n/a | 8 |
| Feb ’25 | US$1.14 | US$2.07 +81.2% | 63.3% | US$4.00 | US$0.63 | n/a | 5 |
| Jan ’25 | US$1.18 | US$2.06 +74.2% | 58.1% | US$4.00 | US$0.63 | n/a | 6 |
| Dec ’24 | US$1.03 | US$2.06 +99.5% | 58.1% | US$4.00 | US$0.63 | n/a | 6 |
| Nov ’24 | US$0.47 | US$2.75 +484.7% | 49.9% | US$5.00 | US$0.75 | US$0.80 | 7 |
| Oct ’24 | US$0.90 | US$3.41 +280.8% | 51.4% | US$7.00 | US$1.40 | US$0.83 | 8 |
| Sep ’24 | US$1.26 | US$3.26 +158.8% | 52.4% | US$7.00 | US$1.40 | US$0.87 | 9 |
| Aug ’24 | US$1.53 | US$3.19 +108.2% | 57.5% | US$7.00 | US$1.40 | US$0.94 | 10 |
| Jul ’24 | US$2.05 | US$4.53 +121.0% | 42.8% | US$7.00 | US$1.70 | US$0.92 | 10 |
| Jun ’24 | US$1.61 | US$4.57 +184.0% | 40.5% | US$7.00 | US$1.70 | US$1.09 | 11 |
| May ’24 | US$2.24 | US$4.76 +112.5% | 33.4% | US$7.00 | US$2.50 | US$1.17 | 10 |
| Apr ’24 | US$2.42 | US$4.63 +91.2% | 34.0% | US$7.00 | US$2.50 | US$1.12 | 11 |
| Mar ’24 | US$2.17 | US$4.32 +98.9% | 39.9% | US$7.00 | US$2.00 | US$1.08 | 12 |
| Feb ’24 | US$2.59 | US$4.32 +66.7% | 39.9% | US$7.00 | US$2.00 | US$1.14 | 12 |
| Jan ’24 | US$1.74 | US$3.87 +122.2% | 51.4% | US$7.00 | US$1.50 | US$1.18 | 12 |
| Dec ’23 | US$1.65 | US$4.21 +154.9% | 42.3% | US$7.00 | US$2.10 | US$1.03 | 13 |
| Nov ’23 | US$2.17 | US$4.97 +129.1% | 33.4% | US$8.00 | US$3.00 | US$0.47 | 13 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
B&G Foods
US$497.9m
Manufactures, sells, and distributes a portfolio of shelf-stable and frozen foods, and household products in the United States, Canada, and Puerto Rico.
BGS
US$6.21
7D
-4.3%
1Y
-34.1%
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas
R$2.4b
Engages in the acquisition, development, exploration, and sale of agricultural activities in Brazil, Paraguay, and Bolivia.
LND
R$4.18
7D
-0.1%
1Y
-15.2%
Meiji Holdings
JP¥890.4b
Through its subsidiaries, engages in the manufacture and sale of dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally.
MEJH.Y
JP¥9.65
7D
-12.3%
1Y
-12.7%